X0306 4 2018-12-06 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001743881 BridgeBio Pharma LLC 421 KIPLING ST. PALO ALTO CA 94301 0 0 1 0 Common Stock 2018-12-06 4 S 0 38970 13.34 A 22507473 D Common Stock 2018-12-07 4 S 0 36314 13.94 A 22543787 D Common Stock 2018-12-07 4 S 0 4860 14.36 A 22548647 D All shares of the Issuer's Common Stock, par value $0.001 per share (the "Common Stock") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the "IPO"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (Continued from Footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO. Represents the weighted average sale price of the shares sold ranging from $12.79 to $13.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price of the shares sold ranging from $13.33 to $14.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price of the shares sold ranging from $13.34 to $14.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. BridgeBio Pharma LLC, By: /s/ Neil Kumar, Name: Neil Kumar, Title: Chief Executive Officer 2018-12-10